About Us

Leukemias are one of the leading causes of cancer-related death in children and adults, despite therapeutic advances that have improved outcomes. Additionally, long-term and late effects of therapies can lead to serious challenges for survivors.

Public Resource of Patient-derived and Expanded Leukemias (PROPEL) is an initiative developed to advance fundamental research on the biology of leukemia and help develop cures by sharing unique xenograft samples with scientists around the world.

PROPEL was developed by the St. Jude Comprehensive Cancer Center Hematological Malignancies Program. Led by co-leaders Charles G. Mullighan, MBBS (Hons), MSc, MD, and Ching-Hon Pui, MD, PROPEL is one of the largest repositories of patient-derived xenografts for adult and pediatric leukemias. Data and xenografts are available to academic researchers without obligation to collaborate.

How to cite this resource

When publishing manuscripts using data or information from PROPEL, please cite St. Jude Children’s Research Hospital PROPEL Data Portal and include https://propel.stjude.cloud.

Contact us

We look forward to your questions as we continue to provide this research community resource. Please contact us at propel@stjude.org.